• Explore /
  • Poster
  • / G1T38, an oral CDK4/6 inhibitor, dosed continuously in combination with fulvestrant for HR+ breast cancer: Preliminary phase 1b results.

G1T38, an oral CDK4/6 inhibitor, dosed continuously in combination with fulvestrant for HR+ breast cancer: Preliminary phase 1b results.

Abstract Poster

Authors

null

Iurie Bulat

ARENSIA Exploratory Medicine Research Unit, Institute of Oncology, Chisinau, Moldova, The Republic of

Iurie Bulat , Marina Maglakelidze , Carmen Murias , Galina Petrova Kurteva , Rebecca Roylance , Maia Gogiladze , Adrian Crijanovschi , Amy McCullough , Elizabeth Shearin , Jessica Sorrentino , Christina Sipes , Zhao Yang , Yaping Cai , Rajesh K. Malik , Andrew Paul Beelen

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Metastatic

Track

Breast Cancer

Sub Track

Hormone Receptor-Positive

Clinical Trial Registration Number

NCT02983071

Citation

J Clin Oncol 36, 2018 (suppl; abstr 1061)

DOI

10.1200/JCO.2018.36.15_suppl.1061

Abstract #

1061

Poster Bd #

142

Abstract Disclosures

Similar Posters

First Author: Dejan Juric

First Author: Tomás Pascual

First Author: Mafalda Oliveira

First Author: Rachel M. Layman